3 results
Approved WMOWill not start
Primary end points:Safety (>1 toxic death per arm) and tolerability (relevant grade 4 toxicities) in not more than 33% of patients for the three treatment arms.Secondary end points:* Reduction of grade 2-4 key side effects in the experimental…
Approved WMOWill not start
To demonstrate that the Cerebral Embolic Protection Device (TriGUARD*3) in patients undergoing Transcatheter Aortic Valve Implantation (TAVI) leads to less brain injury as assessed by transcranial Doppler measurements.
Approved WMORecruiting
The purpose of the study is to provide ongoing post-market demonstration of the safety and performance of the FARAPULSEPulsed Field Ablation System in the treatment of patients with paroxysmal atrial fibrillation (PAF).